Skip to main content

Table 2 Changes in lipid profile of eligible patients before and after treatment

From: Baicalin reduces blood lipids and inflammation in patients with coronary artery disease and rheumatoid arthritis: a randomized, double-blind, placebo-controlled trial

  Baicalin (n = 166) Placebo (n = 165)
Baseline Post treatment Baseline Post treatment
TG (mmol/L) 2.77 ± 1.26 1.12 ± 0.36 * 2.83 ± 1.35 1.87 ± 0.46 *#
TC (mmol/L) 4.62 ± 1.53 2.87 ± 1.23 * 4.75 ± 1.62 3.22 ± 1.07 *#
HDL-C (mmol/L) 0.96 ± 0.35 1.38 ± 0.41 * 1.02 ± 0.24 1.16 ± 0.32 *#
LDL-C (mmol/L) 2.84 ± 0.71 1.73 ± 0.52 * 2.91 ± 0.83 2.42 ± 0.57 *#
ApoA1 (g/L) 1.13 ± 0.22 1.31 ± 0.41 * 1.16 ± 0.27 1.23 ± 0.29 *#
ApoB100 (g/L) 0.83 ± 0.21 0.43 ± 0.11 * 0.86 ± 0.25 0.67 ± 0.23 *#
  1. Values are mean ± SD. *p < 0.05 compared to baseline within the same group; #p < 0.05 compared at the same time point between two groups. TG triglycerides, TC total cholesterol, HDL-C high-density lipoprotein cholesterol, LDL-C low-density lipoprotein cholesterol, ApoA 1 , apolipoprotein A1, ApoB 100 apolipoprotein B100